Jazz Pharmaceuticals PLC $JAZZ Shares Sold by MassMutual Private Wealth & Trust FSB

Key Points

• MassMutual Private Wealth & Trust FSB reduced its stake in Jazz Pharmaceuticals by 50.3% in the 2nd quarter, owning 18,055 shares valued at $1.92 million after selling over 18,000 shares.
• Jazz Pharmaceuticals reported a significant loss of $8.25 earnings per share for the latest quarter, missing analyst expectations, alongside a 2.1% revenue increase year-over-year.
• Equities research analysts have upgraded Jazz Pharmaceuticals, with Goldman Sachs and Morgan Stanley raising their target prices to $185.00 and $163.00 respectively, indicating a positive outlook for the stock.

MassMutual Private Wealth & Trust FSB lowered its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 50.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 18,055 shares of the specialty pharmaceutical company's stock after selling 18,271 shares during the period. MassMutual Private Wealth & Trust FSB's holdings in Jazz Pharmaceuticals were worth $1,916,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Hurley Capital LLC purchased a new position in shares of Jazz Pharmaceuticals in the first quarter valued at $25,000. Elequin Capital LP lifted its stake in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 183 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after buying an additional 119 shares during the period. Spire Wealth Management increased its holdings in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock worth $35,000 after buying an additional 161 shares during the period. Finally, Picton Mahoney Asset Management increased its holdings in shares of Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock worth $34,000 after buying an additional 269 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares in the company, valued at $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Stock Down 2.2%

JAZZ stock traded down $2.89 during trading on Friday, hitting $128.30. 1,488,638 shares of the company's stock traded hands, compared to its average volume of 681,709. The firm has a market capitalization of $7.78 billion, a P/E ratio of -19.06, a PEG ratio of 8.13 and a beta of 0.24. The business has a fifty day simple moving average of $120.39 and a two-hundred day simple moving average of $116.25. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. During the same period in the prior year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals's revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analyst Ratings Changes

JAZZ has been the topic of a number of research analyst reports. Morgan Stanley boosted their price target on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a report on Thursday, August 28th. Royal Bank Of Canada boosted their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a research report on Thursday, August 28th. Zacks Research raised Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target on the stock. Fourteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $178.67.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.